176 related articles for article (PubMed ID: 34503204)
1. TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.
Lecuelle J; Boidot R; Mananet H; Derangère V; Albuisson J; Goussot V; Arnould L; Tharin Z; Ray Coquard I; Ghiringhelli F; Truntzer C; Fumet JD
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503204
[TBL] [Abstract][Full Text] [Related]
2. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
3. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
[TBL] [Abstract][Full Text] [Related]
4. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR
Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253
[TBL] [Abstract][Full Text] [Related]
5. T-Cell Infiltration and Clonality May Identify Distinct Survival Groups in Colorectal Cancer: Development and Validation of a Prognostic Model Based on The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC).
Campana LG; Mansoor W; Hill J; Macutkiewicz C; Curran F; Donnelly D; Hornung B; Charleston P; Bristow R; Lord GM; Valpione S
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497365
[TBL] [Abstract][Full Text] [Related]
6. HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
Koskela H; Li Y; Joutsiniemi T; Muranen T; Isoviita VM; Huhtinen K; Micoli G; Lavikka K; Marchi G; Hietanen S; Virtanen A; Hautaniemi S; Oikkonen J; Hynninen J
Gynecol Oncol; 2024 Jan; 180():91-98. PubMed ID: 38061276
[TBL] [Abstract][Full Text] [Related]
7. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
[TBL] [Abstract][Full Text] [Related]
8. Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.
Fumet JD; Lardenois E; Ray-Coquard I; Harter P; Joly F; Canzler U; Truntzer C; Tredan O; Liebrich C; Lortholary A; Pissaloux D; Leary A; Pfisterer J; Eeckhoutte A; Hilpert F; Fabbro M; Caux C; Alexandre J; Houlier A; Sehouli J; Sohier E; Kimmig R; Dubois B; Spaeth D; Treilleux I; Frenel JS; Herwig U; Le Saux O; Bendriss-Vermare N; du Bois A
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267497
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel prognostic model based on homologous recombination deficiency associated lncRNAs in lung adenocarcinoma.
Liu X; Wang T; Ren Z; Feng C; Tian X
Heliyon; 2023 Apr; 9(4):e14811. PubMed ID: 37089382
[TBL] [Abstract][Full Text] [Related]
10. Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer.
Su R; Liu Y; Wu X; Xiang J; Xi X
Front Mol Biosci; 2021; 8():762741. PubMed ID: 34869593
[No Abstract] [Full Text] [Related]
11. T-Cell Receptor Repertoire Characteristics Associated with Prognostic Significance in High-Grade Serous Ovarian Carcinoma.
Kim JW; Kim S; Yang SY; Joung JG; Hwang S
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107543
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
Takamatsu S; Yoshihara K; Baba T; Shimada M; Yoshida H; Kajiyama H; Oda K; Mandai M; Okamoto A; Enomoto T; Matsumura N
Br J Cancer; 2023 Apr; 128(6):1095-1104. PubMed ID: 36593360
[TBL] [Abstract][Full Text] [Related]
13. Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions.
Zhang M; Ma SC; Tan JL; Wang J; Bai X; Dong ZY; Zhang QX
Front Oncol; 2021; 11():772604. PubMed ID: 34976815
[TBL] [Abstract][Full Text] [Related]
14. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
[TBL] [Abstract][Full Text] [Related]
15. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
16. Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
Pikkusaari S; Tumiati M; Virtanen A; Oikkonen J; Li Y; Perez-Villatoro F; Muranen T; Salko M; Huhtinen K; Kanerva A; Koskela H; Tapper J; Koivisto-Korander R; Joutsiniemi T; Haltia UM; Lassus H; Hautaniemi S; Färkkilä A; Hynninen J; Hietanen S; Carpén O; Kauppi L
Clin Cancer Res; 2023 Aug; 29(16):3110-3123. PubMed ID: 36805632
[TBL] [Abstract][Full Text] [Related]
17. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
18. Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma.
Zhou X; Xu R; Lu T; Xu R; Wang C; Peng B; Chang X; Shen Z; Wang K; Shi J; Zhao J; Zhang LY
Aging (Albany NY); 2023 Aug; 15(16):8090-8112. PubMed ID: 37578930
[TBL] [Abstract][Full Text] [Related]
19. Identification of CXCL13 as a Promising Biomarker for Immune Checkpoint Blockade Therapy and PARP Inhibitor Therapy in Ovarian Cancer.
Ding Y; Ye Z; Ding B; Feng S; Zhang Y; Shen Y
Mol Biotechnol; 2024 Jun; ():. PubMed ID: 38856873
[TBL] [Abstract][Full Text] [Related]
20.
Shi Z; Shen J; Qiu J; Zhao Q; Hua K; Wang H
Theranostics; 2021; 11(15):7175-7187. PubMed ID: 34158843
[No Abstract] [Full Text] [Related]
[Next] [New Search]
